Mga Batayang Estadistika
| LEI | 529900EFNCIRC8Q7V234 |
| CIK | 1264587 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Stemline Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| June 22, 2020 |
15-12B 1 tm2023132d11512b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35619 Stemline Therapeutics, Inc. ( |
|
| June 10, 2020 |
As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. |
|
| June 10, 2020 |
As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. |
|
| June 10, 2020 |
As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. |
|
| June 10, 2020 |
As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. |
|
| June 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 8) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se |
|
| June 10, 2020 |
POS AM 1 tm2021445d12posam.htm POS AM As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. 333-193726 Registration No. 333-219794 Registration No. 333-230341 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-193726 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION |
|
| June 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2020 Stemline Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35619 45-0522567 (State or other Jurisdiction of Incorporation) (Commissi |
|
| June 10, 2020 |
SC TO-T/A 1 tm2021445d10sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) STEMLINE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MERCURY MERGER SUB, INC. a wholly owned subsidiary of BERLIN-CHEMIE AG an indirect wholly own |
|
| June 10, 2020 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF STEMLINE THERAPEUTICS, INC. FIRST: The name of the Corporation is Stemline Therapeutics, Inc. (the “Corporation”). SECOND: The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, Delaware, 19801. The name of its registered agent at that address is The C |
|
| June 10, 2020 |
Exhibit (a)(5)(E) Menarini Group Completes Acquisition of Stemline Therapeutics · Acquisition of Stemline establishes Menarini’s presence in the U. |
|
| June 10, 2020 |
As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. |
|
| June 10, 2020 |
Amended and Restated By-Laws of Stemline Therapeutics, Inc., dated June 10, 2020. EX-3.2 3 tm2021445d5ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF STEMLINE THERAPEUTICS, INC. Article I Offices SECTION 1. Registered Office. The registered office of Stemline Therapeutics, Inc. (the “Corporation”) within the State of Delaware shall be c/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, Wilmington, County of New Castle, Delaware 1980 |
|
| June 10, 2020 |
POS AM 1 tm2021445d6posam.htm POS AM As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. 333-193726 Registration No. 333-219794 Registration No. 333-230341 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-193726 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION |
|
| June 10, 2020 |
As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. |
|
| June 10, 2020 |
As filed with the Securities and Exchange Commission on June 10, 2020 Registration No. |
|
| June 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 7) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se |
|
| June 2, 2020 |
SC TO-T/A 1 tm2021476d1sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) STEMLINE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MERCURY MERGER SUB, INC. a wholly owned subsidiary of BERLIN-CHEMIE AG an indirect wholly owne |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 6) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se |
|
| June 1, 2020 |
SC 14D9/A 1 tm2021445d1sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se |
|
| May 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se |
|
| May 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se |
|
| May 15, 2020 |
SC TO-T/A 1 tm2019872d1sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) STEMLINE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MERCURY MERGER SUB, INC. a wholly owned subsidiary of BERLIN-CHEMIE AG and an indirect wholly |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) Pietro Giovanni Corsa A. Menarini - Industrie Farmaceutiche Riunite - S.r.l. Via Sette Santi, 3 - 50131 - Firenze (Firenze) Italy Tel. +39 0 |
|
| May 12, 2020 |
SC 14D9 1 a2241568zsc14d9.htm SC 14D9 QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Per |
|
| May 12, 2020 |
EX-99.A1E 6 tm2019199-1ex99a1e.htm EXHIBIT 99.A1E Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of STEMLINE THERAPEUTICS, INC. a Delaware corporation at $11.50 NET PER SHARE, PLUS ONE NON-TRANSFERABLE CONTRACTUAL CONTINGENT VALUE RIGHT FOR EACH SHARE, WHICH REPRESENTS THE RIGHT TO RECEIVE A CONTINGENT PAYMENT OF $1.00 PER SHARE UPON THE ACHIEVEMENT OF A SPECIF |
|
| May 12, 2020 |
Form of Letter of Transmittal. ? Exhibit (a)(1)(B)? LETTER OF TRANSMITTAL To Tender Shares of Common Stock of STEMLINE THERAPEUTICS, INC. |
|
| May 12, 2020 |
STEMLINE THERAPEUTICS, INC. CHANGE IN CONTROL SEVERANCE PLAN EX-99.(E)(15) 2 a2241568zex-99e15.htm EX-99.(E)(15) Exhibit (e)(15) STEMLINE THERAPEUTICS, INC. CHANGE IN CONTROL SEVERANCE PLAN The Company has adopted this Change in Control Severance Plan for the benefit of certain employees of the Company, on the terms and conditions hereinafter stated. All capitalized terms used herein are defined in Section 1 hereof. The Plan, as set forth herein, is intende |
|
| May 12, 2020 |
Mutual Confidential Disclosure Agreement, effective July 19, 2019, between Stemline and Menarini. Exhibit (d)(2) STEMLINE MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT This Agreement (the "Agreement") is made as of this 19th day of July 2019, between A. |
|
| May 12, 2020 |
Exhibit (e)(20) Stemline Therapeutics, Inc. 750 Lexington Avenue, 11th Floor New York, NY 10022 www.stemline.com March 1, 2017 PERSONAL & CONFIDENTIAL Robert Francomano Re: Employment with Stemline Therapeutics, Inc. Dear Robert: We are delighted to transition your full-time consulting position which commenced on September 19, 2016, to full employment with an offer to join Stemline Therapeutics, I |
|
| May 12, 2020 |
Power of Attorney for Parent, dated April 30, 2020. Exhibit (a)(1)(G) BERLIN- CHEMIE MENARINI BERLIN-CHEMIE AG Glienicker Weg 125 12489 Berlin POWER OF ATTORNEY The undersigned, Dr. |
|
| May 12, 2020 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.A1D 5 tm2019199-1ex99a1d.htm EXHIBIT 99.A1D Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of STEMLINE THERAPEUTICS, INC. a Delaware corporation at $11.50 NET PER SHARE, PLUS ONE NON-TRANSFERABLE CONTRACTUAL CONTINGENT VALUE RIGHT FOR EACH SHARE, WHICH REPRESENTS THE RIGHT TO RECEIVE A CONTINGENT PAYMENT OF $1.00 PER SHARE UPON THE ACHIEVEMENT OF A SPECIF |
|
| May 12, 2020 |
Offer to Purchase, dated May 12, 2020. TABLE OF CONTENTS Exhibit (a)(1)(A)? Offer to Purchase All Outstanding Shares of Common Stock of STEMLINE THERAPEUTICS, INC. |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 STEMLINE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) MERCURY MERGER SUB, INC. a wholly owned subsidiary of BERLIN-CHEMIE AG an indirect wholly owned subsidiary of A. MENARINI - INDUSTRIE FARMACEUTICHE RIUNITE |
|
| May 12, 2020 |
Form of Summary Advertisement, published May 12, 2020 in The New York Times. Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| May 12, 2020 |
Form of Notice of Guaranteed Delivery. ? Exhibit (a)(1)(C)? NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of STEMLINE THERAPEUTICS, INC. |
|
| May 12, 2020 |
Exclusivity Agreement, dated April 13, 2020, between Stemline and Menarini. Exhibit (d)(5) Strictly Private & Confidential 13 April 2020 Dr. Ivan Bergstein, M.D. Chairman, Chief Executive Officer and President Stemline Therapeutics, Inc. 750 Lexington Avenue, 11th Floor New York, NY 10022 Re: Exclusivity Agreement Dear Ivan: This letter agreement (this ?Letter Agreement?) sets forth certain agreements of Stemline Therapeutics, Inc. (?the ?Company?) with respect to a possi |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STEMLINE THERAPEUTICS |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 STEMLINE THERAPEUTICS, INC. (Name of Subject Company) MERCURY MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of BERLIN-CHEMIE AG (Parent of Offeror) And An Indirect Wholly Owned Subsidiary of A. MENARINI - INDUSTR |
|
| May 5, 2020 |
Exhibit 99.1 LinkedIn Post by Menarini Group MENARINI Group Menarini Group today announced a definitive agreement under which it will acquire Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Elcin Barker Ergun, CEO of Menarini Group, commented, ?Stemline is an excellent fit for Menarini, enabling us |
|
| May 4, 2020 |
FORM OF TENDER AND SUPPORT AGREEMENT Exhibit 99.1 FORM OF TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of May 3, 2020, is entered into by and among Berlin-Chemie AG, a company formed under the laws of Germany (“Parent”), Mercury Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and the stockholder listed on the signature page hereto (the “Sto |
|
| May 4, 2020 |
EX-2.1 2 tm2018457d1ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: STEMLINE THERAPEUTICS, INC., a Delaware corporation; BERLIN-CHEMIE AG, a company formed under the laws of Germany; and MERCURY MERGER SUB, INC., a Delaware corporation Dated as of May 3, 2020 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 6 Section 2 MERGER TRANSAC |
|
| May 4, 2020 |
EX-99.3 4 tm2018463d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Stemline Employee FAQ 1) What did Stemline announce? · We announced that we have agreed to be acquired by Menarini Group in a transaction valued up to approximately $677 million. · Upon closing of the transaction, Stemline shareholders will receive $11.50 per share in cash. In addition, shareholders will receive one non-tradeable Contingent |
|
| May 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 STEMLINE THERAPEUTICS, INC. (Name of Subject Company) MERCURY MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of BERLIN-CHEMIE AG (Parent of Offeror) And An Indirect Wholly Owned Subsidiary of A. MENARINI - INDUSTR |
|
| May 4, 2020 |
EX-99.2 3 tm2018463d1ex99-2.htm EXHIBIT 2 Exhibit 99.2 Dear Stemline Team, I trust this letter finds you and your families in good health in these difficult times. I am reaching out this morning with a significant development for Stemline. Just moments ago, we announced that Stemline has agreed to be acquired by the Menarini Group for up to approximately $677 million or $11.50 a share at closing p |
|
| May 4, 2020 |
SC14D9C 1 tm2018463-1sc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Subject Company) Stemline Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per shar |
|
| May 4, 2020 |
Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million May 4, 2020 • Acquisition of Stemline establishes Menarini’s presence in the U. |
|
| May 4, 2020 |
Amendment to Stemline’s Amended and Restated Bylaws, dated May 3, 2020 EX-3.1 3 tm2018457d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 Amendment to the Amended and Restated Bylaws of Stemline Therapeutics, Inc. Article XII EXCLUSIVE FORUM 7.1 Forum for Adjudication of Certain Disputes. Unless the Corporation consents in writing to the selection of an alternative forum (an “Alternative Forum Consent”), the Court of Chancery of the State of Delaware shall be the sole and exclusi |
|
| May 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2020 Stemline Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35619 45-0522567 (State or other Jurisdiction of Incorporation) (Commission |
|
| May 4, 2020 |
Joint Press Release, dated May 4, 2020 Exhibit 99.1 Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million · Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market · Menarini will support further development of Stemline’s ELZONRIS® and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies · Total pot |
|
| May 4, 2020 |
Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million Exhibit 99.2 Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million · Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market · Menarini will support further development of Stemline’s ELZONRIS® and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies · Total pot |
|
| April 29, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 16, 2020 |
STML / Stemline Therapeutics, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35619 STEMLINE THERAPEUTICS, |
|
| March 16, 2020 |
List of subsidiaries of Stemline Therapeutics, Inc. EX-21.1 3 tm2031081d1ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 STEMLINE THERAPEUTICS, INC. List of Subsidiaries Stemline Therapeutics, Inc. does not have any subsidiaries. |
|
| March 16, 2020 |
Description of Securities of Stemline Therapeutics, Inc. Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 When used herein, the terms “we,” “our,” and “us” refer to Stemline Therapeutics, Inc. DESCRIPTION OF COMMON STOCK Common Stock Under the terms of our restated certificate of incorporation, as amended, we are authorized to issue a total of 83,750,000 shares of common stoc |
|
| March 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2020 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number |
|
| March 13, 2020 |
Liabilities and stockholders’ equity Exhibit 99.1 Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results · Net revenue for ELZONRIS® was $11.8 million for the fourth quarter · Conference call and live webcast scheduled for Monday, March 16th, at 8:00 AM ET NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) - Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and com |
|
| February 18, 2020 |
STML / Stemline Therapeutics, Inc. / Bergstein Ivan - SC 13G/A Passive Investment SC 13G/A 1 a20-81821sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 14, 2020 |
STML / Stemline Therapeutics, Inc. / Rubric Capital Management LP - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Stemline Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| February 12, 2020 |
SC 13G 1 stml3721221-sc13g.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Stemline Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 12, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| February 4, 2020 |
STML / Stemline Therapeutics, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SC 13G 1 stemlinetherapeutics13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Chec |
|
| November 12, 2019 |
STML / Stemline Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 a19-17602110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a19-2218718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2019 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001- |
|
| November 7, 2019 |
Exhibit 99.1 Stemline Therapeutics Reports Third Quarter 2019 Financial Results · Net revenue for ELZONRIS® was $13.3 million for the third quarter · New patient starts estimated to have increased greater than 20% from last quarter · Conference call and live webcast scheduled for tomorrow, Friday November 8th, at 8:00 AM ET NEW YORK, November 7, 2019 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. |
|
| August 9, 2019 |
EX-1.1 2 a19-169081ex1d1.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION STEMLINE THERAPEUTICS, INC. UNDERWRITING AGREEMENT August 8, 2019 J.P. Morgan Securities LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: The undersigned, Stemline Therapeutics, Inc., a corporation formed und |
|
| August 9, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2019 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2019 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230341 Prospectus supplement (to Prospectus dated May 1, 2019) 5,000,000 Shares Common stock We are offering 5,000,000 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Capital Market under the symbol “STML.” On August 8, 2019 the last reported sale price of our common stock on The Nasdaq Ca |
|
| August 8, 2019 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230341 Subject to completion Preliminary prospectus supplement dated August 8, 2019 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary pr |
|
| August 6, 2019 |
Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, 10-Q 1 a19-10373110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| August 2, 2019 |
Exhibit 99.1 Stemline Therapeutics Reports Second Quarter 2019 Financial Results · Net revenue for ELZONRIS® was $13.0 million for the second quarter · Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, August 2, 2019 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization |
|
| August 2, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2019 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 28, 2019 |
STML / Stemline Therapeutics, Inc. S-8 - - S-8 S-8 1 a19-121798s8.htm S-8 As filed with the Securities and Exchange Commission on June 28, 2019 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEMLINE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-0522567 (State or other jurisdiction of incorporation or or |
|
| June 28, 2019 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF STEMLINE THERAPEUTICS, INC. June 26, 2019 Stemline Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the “DGCL”), does hereby certify: FIRST: That the Board of Directors of the Corporation (the “Board”), pursuant to a unanimous written cons |
|
| June 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2019 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number) |
|
| June 11, 2019 |
STML / Stemline Therapeutics, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| June 11, 2019 |
STML / Stemline Therapeutics, Inc. PX14A6G - - PX14A6G PX14A6G 1 formpx14a6g.htm PX14A6G Name of Registrant: Stemline Therapeutics, Inc. Name of persons relying on exemption: California Public Employees Retirement System (CalPERS) Address of persons relying on exemption: 400 Q Street, Sacramento, CA 95811 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required of th |
|
| May 10, 2019 |
EX-99.1 2 a19-97691ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Reports First Quarter 2019 Financial Results · Net revenue for ELZONRIS was $5.05 million for the first quarter · Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the |
|
| May 10, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a19-976918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2019 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 |
|
| May 10, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STE |
|
| April 30, 2019 |
STML / Stemline Therapeutics, Inc. DEFA14A DEFA14A DEFA14A 1 a19-25802defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as |
|
| April 30, 2019 |
DEF 14A 1 a19-25801def14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Co |
|
| April 30, 2019 |
STML / Stemline Therapeutics, Inc. CORRESP - - Stemline Therapeutics, Inc. April 30, 2019 Securities and Exchange Commission Department of Corporation Finance Washington, D.C. 20549 Attn: Ms. Tonya K. Aldave Via: EDGAR Submission Re: Stemline Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-230341 Ladies and Gentlemen: Stemline Therapeutics, Inc. (the “Company”), hereby requests that the effective date for the Registration St |
|
| April 29, 2019 |
Stemline Therapeutics Announces Exhibit 99.1 Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the pivotal trial results of |
|
| April 29, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2019 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number |
|
| April 19, 2019 |
STML / Stemline Therapeutics, Inc. PRE 14A PRE 14A 1 a19-25801pre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Co |
|
| March 15, 2019 |
STML / Stemline Therapeutics, Inc. S-3 Table of Contents As filed with the Securities and Exchange Commission on March 15, 2019. |
|
| March 15, 2019 |
Form of Indenture (filed herewith) Exhibit 4.6 STEMLINE THERAPEUTICS, INC. FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [ ] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Act Section Indenture Section §310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 §311 11.01(f), 16.02 §312 14.02(d), 16.02 (b |
|
| March 15, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a19-655018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2019 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-356 |
|
| March 15, 2019 |
Exhibit 99.1 Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results NEW YORK, Mar. 15, 2019 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today financial results for the quarter ended December 31, 2018. The Company also reviewed recen |
|
| March 15, 2019 |
List of subsidiaries of Stemline Therapeutics, Inc. Exhibit 21.1 STEMLINE THERAPEUTICS, INC. List of Subsidiaries Stemline Therapeutics, Inc. does not have any subsidiaries. |
|
| March 15, 2019 |
Our Annual Report on Form 10-K for the year ended December 31, 2018; 10-K 1 a19-30101110k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commissio |
|
| February 22, 2019 |
SC 13G 1 p19-0689sc13g.htm STEMLINE THERAPEUTICS INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) February 14, 2019 (Date of Event Which Requires Filing of This Statement) |
|
| February 14, 2019 |
SC 13G/A 1 stmla121419.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* STEMLINE THERAPEUTICS INC (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| February 11, 2019 |
STML / Stemline Therapeutics, Inc. / Bergstein Ivan - SC 13G/A Passive Investment SC 13G/A 1 a19-42535sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check t |
|
| January 16, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a19-295018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 15, 2019 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of |
|
| January 16, 2019 |
Exhibit 1.1 EXECUTION VERSION STEMLINE THERAPEUTICS, INC. UNDERWRITING AGREEMENT January 15, 2019 J.P. Morgan Securities LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: The und |
|
| January 16, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 15, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| December 21, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Num |
|
| December 21, 2018 |
Exhibit 99.1 FDA Approves ELZONRISTM (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy · ELZONRIS is approved to treat adult and pediatric patients with both treatment-naïve and previously-treated BPDCN · Conference call scheduled for Friday, December 21, 2018 at 4:30 PM ET: Toll Free: (888) 254-3590 or (323) 994-2093; Confirmation |
|
| November 8, 2018 |
September 30, 2018 (Unaudited) Exhibit 99.1 Stemline Therapeutics Reports Third Quarter 2018 Financial Results NEW YORK, November 8, 2018 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced today financial results for the quarter ended September 30, 2018. The Company also reviewed recent cl |
|
| November 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 8, 2018 |
STML / Stemline Therapeutics, Inc. 10-Q (Quarterly Report) 10-Q 1 a18-19033110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co |
|
| August 13, 2018 |
Stemline Therapeutics Announces that FDA Accepts ELZONRIS Exhibit 99.1 Stemline Therapeutics Announces that FDA Accepts ELZONRISTM Biologics License Application (BLA) and Grants Priority Review · Conference call on BLA acceptance and commercial readiness scheduled for Monday, August 13, 2018 at 8:30 AM ET NEW YORK, August 13, 2018 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel on |
|
| August 13, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Numbe |
|
| August 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a18-1853318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35 |
|
| August 9, 2018 |
EX-99.1 2 a18-185331ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Reports Second Quarter 2018 Financial Results NEW YORK, August 9, 2018 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today its financial results for the quarter ended June 30, 2018. The Company also reviewed recent c |
|
| August 9, 2018 |
STML / Stemline Therapeutics, Inc. 10-Q (Quarterly Report) 10-Q 1 a18-14093110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| July 2, 2018 |
As filed with the Securities and Exchange Commission on July 2, 2018 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEMLINE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-0522567 (State or other jurisdiction of incorporation or organization) (IRS Employer Id |
|
| June 26, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number) |
|
| June 26, 2018 |
Exhibit 99.1 Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has completed submission of a rolling Biologics License Appli |
|
| June 22, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction (Commission File Number) (IRS E |
|
| May 10, 2018 |
STML / Stemline Therapeutics, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STE |
|
| May 10, 2018 |
Exhibit 99.1 Stemline Therapeutics Reports First Quarter 2018 Financial Results NEW YORK, May 9, 2018 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial results for the quarter ended March 31, 2018. The Company also reviewed recent clinical and regulatory events, and outlined ke |
|
| May 10, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a18-1313218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-3561 |
|
| April 30, 2018 |
STML / Stemline Therapeutics, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 30, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number |
|
| March 16, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number |
|
| March 16, 2018 |
Exhibit 1.1 DISTRIBUTION AGREEMENT March 16, 2018 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 26th Floor New York, NY 10172 Ladies and Gentlemen: Stemline Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (the “Company”), confirms its a |
|
| March 16, 2018 |
Use these links to rapidly review the document Table of contents Table of Contents Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| March 16, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 16, 2018 |
Exhibit 99.1 Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial results for the quarter ended December 31, 2017. The Company also reviewed recent clinical and regulatory events, and outl |
|
| March 16, 2018 |
List of subsidiaries of Stemline Therapeutics, Inc. Exhibit 21.1 STEMLINE THERAPEUTICS, INC. List of Subsidiaries Stemline Therapeutics, Inc. does not have any subsidiaries. |
|
| March 16, 2018 |
STML / Stemline Therapeutics, Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35619 STEML |
|
| February 14, 2018 |
STML / Stemline Therapeutics, Inc. / Bergstein Ivan - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2018 |
SC 13G 1 stml21418.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 STEMLINE THERAPEUTICS INC (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the ap |
|
| February 13, 2018 |
SC 13G/A 1 p18-0165sc13ga.htm STEMLINE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of This St |
|
| February 7, 2018 |
STML / Stemline Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment stem17a5.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 85858C107 13G Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2017 |
|
| January 24, 2018 |
Exhibit 1.1 EXECUTION VERSION STEMLINE THERAPEUTICS, INC. UNDERWRITING AGREEMENT January 23, 2018 J.P. Morgan Securities LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: The und |
|
| January 24, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2018 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 24, 2018 |
424B5 1 a2234353z424b5.htm 424B5 Use these links to rapidly review the document Table of contents Table of Contents Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219794 Prospectus supplement (to Prospectus dated August 18, 2017) 3,700,000 Shares Common stock We are offering 3,700,000 shares of our common stock in this offering. Our common stock is listed on The NASDAQ Cap |
|
| January 22, 2018 |
424B5 1 a2234051z424b5.htm 424B5 Use these links to rapidly review the document Table of contents Table of Contents Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219794 Subject to completion Preliminary prospectus supplement dated January 22, 2018 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relatin |
|
| December 13, 2017 |
Stemline Therapeutics, Inc. NASDAQ: STML Analyst and Investor Meeting ASH 2017 December 11, 2017 Exhibit 99.2 Stemline Therapeutics, Inc. NASDAQ: STML Analyst and Investor Meeting ASH 2017 December 11, 2017 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ??forward-looking statements.?? In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms ?believes,? ?potentially,? ?estimate |
|
| December 13, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Num |
|
| December 13, 2017 |
Exhibit 99.1 Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented NEW YORK, NY, December 13, 2017 (GLOBE NEWSWIRE)?Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat |
|
| November 9, 2017 |
September 30, 2017 (Unaudited) Exhibit 99.1 Stemline Therapeutics Reports Third Quarter 2017 Financial Results NEW YORK, NY, November 9, 2017 (GLOBE NEWSWIRE)?Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the quarter ended September 30, 2017. The Company also reviewed recent clinical and r |
|
| November 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction (Commission File Number) (IR |
|
| November 9, 2017 |
STML / Stemline Therapeutics, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 |
|
| November 9, 2017 |
STML / Stemline Therapeutics, Inc. / Adage Capital Partners GP LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) October 31, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| November 1, 2017 |
Exhibit 99.1 Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint October 31, 2017 ? Detailed results will be presented at the ASH 2017 Annual Meeting (Dec. 9-12) ? Based on FDA feedback, BLA filing remains on-track ? Conference call scheduled for today, Tuesday, October 31, 2017 at 8:30AM ET NEW YORK, Oct. 31, |
|
| November 1, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Numb |
|
| August 17, 2017 |
STML / Stemline Therapeutics, Inc. ESP Stemline Therapeutics, Inc. August 17, 2017 Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance Washington, D.C. 20549 Attn: Ms. Christine Westbrook Via: EDGAR Submission Re: Stemline Therapeutics, Inc. Registration Statement on Form S-3 Filed August 8, 2017 File No. 333-219794 Ladies and Gentlemen: Stemline Therapeutics, Inc. (the ?Company?), hereby |
|
| August 8, 2017 |
S-8 1 a17-190261s8.htm S-8 As filed with the Securities and Exchange Commission on August 8, 2017 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEMLINE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-0522567 (State or other jurisdiction of incorporation or o |
|
| August 8, 2017 |
Use these links to rapidly review the document Table of Contents Table of Contents As filed with the Securities and Exchange Commission on August 8, 2017. |
|
| August 8, 2017 |
Exhibit 4.6 STEMLINE THERAPEUTICS, INC. FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [ ] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Act Section Indenture Section §310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 §311 11.01(f), 16.02 §312 14.02(d), 16.02 (b |
|
| August 8, 2017 |
Calculation of Ratio/Deficiency of Earnings to Fixed Charges Exhibit 12.1 RATIO OF EARNINGS/ DEFICIENCY TO FIXED CHARGES The following table sets forth, for each of the periods presented, our ratio of earnings to fixed charges and our coverage deficiency. You should read this table in conjunction with the financial statements and notes incorporated by reference in this prospectus. (in thousands) Six Months Ended June 30, 2017 Year Ended December 31, 2016 Ye |
|
| August 8, 2017 |
EX-99.1 2 a17-190761ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Reports Second Quarter 2017 Financial Results NEW YORK, NY, August 8, 2017 (GLOBE NEWSWIRE)—Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the quarter ended June 30, 2017. The Company al |
|
| August 8, 2017 |
Stemline Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number |
|
| August 8, 2017 |
STML / Stemline Therapeutics, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STEM |
|
| August 8, 2017 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF STEMLINE THERAPEUTICS, INC. June 20, 2017 Stemline Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the “DGCL”), does hereby certify: FIRST: That the Board of Directors of the Corporation (the “Board”), pursuant to a unanimous wri |
|
| June 20, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 a17-1543818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction (Com |
|
| May 10, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a17-1287518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-3561 |
|
| May 10, 2017 |
EX-99.1 2 a17-128751ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Reports First Quarter 2017 Financial Results NEW YORK, NY, May 10, 2017 (GLOBE NEWSWIRE)—Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today financial results for the quarter ended March 31, 2017. |
|
| May 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STE |
|
| May 1, 2017 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 21, 2017 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 24, 2017 |
Exhibit 99.1 Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN NEW YORK, NY, March 23, 2017 (GLOBE NEWSWIRE)?Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today that enrollment of Stage 3 in the SL-401 pivotal trial |
|
| March 24, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number |
|
| March 17, 2017 |
Exhibit 99.1 Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results NEW YORK, NY, March 16, 2017 (GLOBE NEWSWIRE)?Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today financial results for the quarter ended December 31, 2016. The company also reviewed clinica |
|
| March 17, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number |
|
| March 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 a17-1159110k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission |
|
| March 16, 2017 |
Stemline Therapeutics, Inc. List of Subsidiaries Exhibit 21.1 Stemline Therapeutics, Inc. List of Subsidiaries Stemline Therapeutics, Inc. does not have any subsidiaries. |
|
| February 14, 2017 |
STML / Stemline Therapeutics, Inc. / Bergstein Ivan - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 13, 2017 |
Schedule 13G Amendment No. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 9, 2017 |
STML / Stemline Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 stem16a4.htm CUSIP NO. 85858C107 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Fi |
|
| January 20, 2017 |
EX-1.1 2 a17-29151ex1d1.htm EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT between STEMLINE THERAPEUTICS, INC. and JEFFERIES LLC as Representative of the Several Underwriters STEMLINE THERAPEUTICS, INC. UNDERWRITING AGREEMENT New York, New York January 20, 2017 Jefferies LLC 520 Madison Avenue New York, New York 10022 As Representative of the several Underwriters named on Schedule 1 attached hereto Lad |
|
| January 20, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 20, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 20, 2017 |
Use these links to rapidly review the document Table of Contents Table of Contents Table of Contents PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2014) Filed pursuant to rule 424(b)(5) Registration No. |
|
| January 19, 2017 |
Use these links to rapidly review the document Table of Contents Table of Contents Table of Contents The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| January 6, 2017 |
EX-99.1 2 a17-15121ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Announces Positive FDA Meeting and Agreement on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN · Ongoing Phase 2 trial with additional small cohort (8-12 patients planned) sufficient for BLA filing for full approval · Approximately half of new cohort patients already enrolled, with full enrollment expected t |
|
| January 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2017 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2016 |
September 30, 2016 (Unaudited) EX-99.1 2 a16-212551ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Reports Third Quarter 2016 Financial Results and Highlights Recent Regulatory and Clinical Progress NEW YORK, November 08, 2016 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended September 30, 2016. Ivan Bergstein, M.D., Stemline’s Chief Executive Officer, comm |
|
| November 8, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2016 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Numb |
|
| November 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 |
|
| August 25, 2016 |
Exhibit 99.1 ` Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401 NEW YORK, August 23, 2016 (GLOBE NEWSWIRE) ? Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to SL-401, a targeted therapy directed to the interleukin-3 receptor (CD12 |
|
| August 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2016 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Numbe |
|
| August 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STEM |
|
| August 4, 2016 |
Exhibit 99.1 Stemline Therapeutics Reports Second Quarter 2016 Financial Results and Highlights Recent Clinical Progress NEW YORK, August 4, 2016 (GLOBE NEWSWIRE) ? Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended June 30, 2016. Clinical highlights and milestones include: SL-401 in blastic plasmacytoid dendritic cell neoplasm (BPDCN) ? Oral presentat |
|
| August 4, 2016 |
Stemline Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2016 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number |
|
| June 6, 2016 |
Exhibit 99.1 Stemline Therapeutics? SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds NEW YORK, June 4, 2016 (GLOBE NEWSWIRE) ? Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blasti |
|
| June 6, 2016 |
Stemline Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2016 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number) |
|
| June 2, 2016 |
As filed with the Securities and Exchange Commission on June 2, 2016 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEMLINE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-0522567 (State or other jurisdiction of incorporation or organization) (IRS Employer Id |
|
| May 25, 2016 |
Stemline Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2016 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number) |
|
| May 9, 2016 |
Exhibit 99.1 Stemline Therapeutics Reports First Quarter 2016 Financial Results NEW YORK, May 9, 2016 (GLOBE NEWSWIRE) ? Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended March 31, 2016. Ivan Bergstein, M.D., Stemline?s Chief Executive Officer, commented, ?During the first quarter, we made substantial progress across our multiple clinical programs. In |
|
| May 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2016 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number) 4 |
|
| May 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STE |
|
| May 9, 2016 |
STML / Stemline Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment CUSIP NO. 85858C107 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) April 30, 2016 (Date of Event Which Requires Filing of this Statement) Che |
|
| April 8, 2016 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 14, 2016 |
Exhibit 99.1 Stemline Therapeutics Reports Fourth Quarter 2015 Financial Results NEW YORK, March 14, 2016 (GLOBE NEWSWIRE) ? Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended December 31, 2015. Ivan Bergstein, M.D., Stemline?s Chief Executive Officer, commented, ?During the fourth quarter, we made significant progress across all three of our developme |
|
| March 14, 2016 |
Stemline Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2016 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number |
|
| March 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 a15-23369110k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commissio |
|
| March 14, 2016 |
Stemline Therapeutics, Inc. List of Subsidiaries Exhibit 21.1 Stemline Therapeutics, Inc. List of Subsidiaries Stemline Therapeutics, Inc. does not have any subsidiaries. |
|
| February 16, 2016 |
STML / Stemline Therapeutics, Inc. / Bergstein Ivan - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 10, 2016 |
STML / Stemline Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment CUSIP NO. 85858C107 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) |
|
| February 10, 2016 |
STML / Stemline Therapeutics, Inc. / TimesSquare Capital Management, LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )1 Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 13, 2016 |
Exhibit 10.1 EMPLOYMENT AGREEMENT Kenneth Hoberman (the ?Executive?) has been employed by Stemline Therapeutics, Inc. (the ?Company?), a Delaware corporation, since March 2012 (each, a ?Party? and both, ?Parties?). The Compensation Committee (the ?Compensation Committee?) of the Board of Directors of the Company (the ?Board?) has determined that it is in the best interests of the Company to enter |
|
| January 13, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2016 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Numbe |
|
| December 10, 2015 |
EX-99.1 2 a15-246901ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Presents Clinical Update from Ongoing SL-401 Pivotal BPDCN Trial at the American Society of Hematology (ASH) Annual Meeting NEW YORK, December 7, 2015 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the presentation of positive clinical data, including high response rates, from the lead-in and on |
|
| December 10, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 7, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Numb |
|
| November 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 |
|
| November 6, 2015 |
September 30, 2015 (Unaudited) Exhibit 99.1 Stemline Therapeutics Reports Third Quarter 2015 Financial Results NEW YORK, November 6, 2015 (GLOBE NEWSWIRE) ? Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended September 30, 2015. Ivan Bergstein, M.D., Stemline?s Chief Executive Officer, commented, ?During the third quarter, we made significant progress on many fronts as we continue to |
|
| November 6, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-2252318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001- |
|
| October 29, 2015 |
EX-10.1 2 a15-219731ex10d1.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is made and entered into between ERIC ROWINSKY, M.D. (“Executive”) and STEMLINE THERAPEUTICS, INC. (the “Company”). WITNESSETH: WHEREAS, Executive and the Company are parties to that certain Employment Agreement, dated November 6, 2011 (the “Employment Agreement”) |
|
| October 29, 2015 |
8-K 1 a15-2197318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 27, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001- |
|
| August 11, 2015 |
As filed with the Securities and Exchange Commission on August 11, 2015 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEMLINE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 45-0522567 (IRS Employer |
|
| August 10, 2015 |
Exhibit 99.1 Stemline Therapeutics Reports Second Quarter 2015 Financial Results NEW YORK, August 10, 2015 (GLOBE NEWSWIRE) ? Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel oncology drugs that primarily target cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended June 30, 2015. Ivan Bergstein, M.D., S |
|
| August 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STEM |
|
| August 10, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Numbe |
|
| June 23, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 a15-1462018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-356 |
|
| May 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STE |
|
| May 11, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number) |
|
| May 11, 2015 |
EX-99.1 2 a15-113251ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Reports First Quarter 2015 Financial Results NEW YORK, May 11, 2015 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended March 31, 2015. Ivan Ber |
|
| April 30, 2015 |
DEF 14A 1 a2224488zdef14a.htm DEF 14A Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check t |
|
| April 27, 2015 |
8-K 1 a15-982418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-356 |
|
| March 16, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-679218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-356 |
|
| March 16, 2015 |
Stemline Therapeutics, Inc. List of Subsidiaries Exhibit 21.1 Stemline Therapeutics, Inc. List of Subsidiaries Stemline Therapeutics, Inc. does not have any subsidiaries. |
|
| March 16, 2015 |
Exhibit 10.31 AMENDMENT TO THE STEMLINE THERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN This Amendment to the Stemline Therapeutics, Inc. 2012 Equity Incentive Plan (the ?Plan?), is hereby adopted this 13th day of March, 2015, by the Board of Directors (the ?Board?) of Stemline Therapeutics, Inc. (the ?Company?). W I T N E S S E T H: WHEREAS, the Company adopted the Plan for the purposes set forth t |
|
| March 16, 2015 |
EX-99.1 2 a15-67921ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Reports Fourth Quarter 2014 Financial Results NEW YORK, March 13, 2015 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended December 31, 2014. Iva |
|
| March 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 a14-25823110k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commissio |
|
| March 16, 2015 |
Exhibit 10.32 AMENDMENT TO THE STEMLINE THERAPEUTICS, INC. AMENDED AND RESTATED 2004 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN This Amendment to the Stemline Therapeutics, Inc. Amended and Restated 2004 Employee, Director and Consultant Stock Plan (the ?Plan?), is hereby adopted this 13th day of March, 2015, by the Board of Directors (the ?Board?) of Stemline Therapeutics, Inc. (the ?Company?). |
|
| March 16, 2015 |
Exhibit 10.30 CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of this document have been redacted and have been separately filed with the Commission. EXECUTION COPY CONFIDENTIAL EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (the “Agreement”) is made and entered into as of December 26, 2014 (the “Execution Date”) by and between CanBas Co., Ltd, a Japanese corporation, having |
|
| March 6, 2015 |
STML / Stemline Therapeutics, Inc. / Bergstein Ivan - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 17, 2015 |
STML / Stemline Therapeutics, Inc. / Baker Brothers Advisors LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2015 |
SC 13G/A 1 stml13gadec14.htm STML AS OF 12/31/2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) STEMLINE THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of Statement) Check the appropriate b |
|
| February 11, 2015 |
STML / Stemline Therapeutics, Inc. / TimesSquare Capital Management, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )1 Stemline Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 6, 2015 |
STML / Stemline Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment stem14a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 85858C107 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* STEMLINE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 85858C107 (CUSIP Number) December 31, 2014 |
|
| January 8, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 8, 2015 |
Use these links to rapidly review the document Table of Contents Table of Contents Table of Contents PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2014) Filed pursuant to Rule 424(b)(5) Registration No. |
|
| January 8, 2015 |
EX-1.1 2 a15-12672ex1d1.htm EX-1.1 Exhibit 1.1 Execution Version UNDERWRITING AGREEMENT between STEMLINE THERAPEUTICS, INC. and JEFFERIES LLC as Representative of the Several Underwriters STEMLINE THERAPEUTICS, INC. UNDERWRITING AGREEMENT New York, New York January 8, 2015 Jefferies LLC 520 Madison Avenue New York, New York 10022 As Representative of the several Underwriters named on Schedule 1 at |
|
| January 7, 2015 |
EX-99.1 2 a15-12671ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics In-Licenses Novel Oral Small Molecule Nuclear Transport Inhibitor Targeting XPO1 Reversible XPO1 Inhibitor offers potential for enhanced therapeutic index and dosing flexibility; IND expected in 2015 NEW YORK, January 7, 2015 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Stemline) (Nasdaq:STML) announced today that it has e |
|
| January 7, 2015 |
8-K 1 a15-126718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2015 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35 |
|
| January 7, 2015 |
SUBJECT TO COMPLETION, DATED JANUARY 7, 2015 424B5 1 a2222630z424b5.htm 424B5 Use these links to rapidly review the document Table of Contents Table of Contents Table of Contents The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This pr |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 |
|
| November 12, 2014 |
September 30, 2014 (Unaudited) Exhibit 99.1 Stemline Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update NEW YORK, November 12, 2014 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended September 30, 2014 and provi |
|
| November 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a14-2429618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2014 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001 |
|
| August 14, 2014 |
EX-99.1 2 a14-190021ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Provides Second Quarter 2014 Financial Results And Corporate Update NEW YORK, August 14, 2014 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today provided a corporate update and reported financ |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STEM |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2014 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2014 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35619 45-0522567 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 28, 2014 |
EX-99.1 2 a14-178891ex99d1.htm EX-99.1 Exhibit 99.1 Stemline Therapeutics Announces Opening of SL-401 Corporate IND and Start of Clinical Trials in BPDCN and AML Initiation of Broad Clinical Development Program; Potential Accelerated Approval Path in Multiple Indications NEW YORK, July 28, 2014 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the opening of its SL-401 I |
|
| June 23, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2014 Stemline Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35619 (Commission File Number) |
|
| May 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35619 STE |
